# Emergent BioSolutions Inc. (EBS) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Pharmaceuticals. Price $6.21, market value $318 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Emergent BioSolutions Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **PEG: 0.05**. A PEG of 0.05 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 0.4×**. Each dollar of revenue is priced at 0.4×, a low multiple typical of thin-margin businesses or out-of-favour stocks.
- **Price / book: 0.9×**. The shares trade below book value, which can signal a bargain or a balance sheet the market doubts.
- **EV / EBITDA: 24.1×**. Enterprise value is 24.1× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 27.0%** (5-yr avg -40.3%). Free cash flow equals 27.0% of the market value, above its five-year average of -40.3%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.

## Profitability
- **Operating margin: -8.6%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: 7.1%**. 7.1% of each dollar of sales reaches the bottom line.
- **Return on equity: 10.1%**. 10.1% on shareholders' equity is solid.
- **Return on invested capital: -5.9%**. Return on all capital, debt included, is -5.9%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -13.4%**. Each dollar of assets produces -13.4% of profit.

## Growth
- **Revenue growth (1 yr): -28.8%** (3-yr -12.7%/yr, 5-yr -13.7%/yr). Revenue fell 28.8% over the last year, against -13.7% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 125.8%** (5-yr -30.4%/yr). Earnings per share rose 125.8%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 1.09**. Debt is 1.09 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Net debt / EBITDA: 12.9×**. It would take 12.9 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Altman Z-score: 1.61**. A Z-score of 1.61 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Emergent BioSolutions Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (2 analysts). 2 analysts cover Emergent BioSolutions Inc.; the consensus is buy, with an average price target of $11.00 (+77% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -18.6%** (YTD -49.8%, 3-mo -23.0%). The shares are down 18.6% over twelve months including dividends.
- **From 52-week high: -55.8%** (42.4% above the low). Trading 56% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 54**. An RSI of 54 is neutral.
- **Beta (1 yr): 1.15** (volatility 78%). Beta of 1.15 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=EBS · Page: https://foliofundamentals.com/stocks/ebs

Not investment advice.